PE20191356A1 - Suministro de proteinas basado en bacterias con virulencia atenuada - Google Patents

Suministro de proteinas basado en bacterias con virulencia atenuada

Info

Publication number
PE20191356A1
PE20191356A1 PE2019001289A PE2019001289A PE20191356A1 PE 20191356 A1 PE20191356 A1 PE 20191356A1 PE 2019001289 A PE2019001289 A PE 2019001289A PE 2019001289 A PE2019001289 A PE 2019001289A PE 20191356 A1 PE20191356 A1 PE 20191356A1
Authority
PE
Peru
Prior art keywords
bacteria
supply based
attenuated virulence
protein supply
virulence
Prior art date
Application number
PE2019001289A
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of PE20191356A1 publication Critical patent/PE20191356A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a cepas bacterianas gramnegativas con virulencia atenuada recombinantes y su uso en un metodo para tratar el cancer en un sujeto
PE2019001289A 2016-12-20 2017-12-20 Suministro de proteinas basado en bacterias con virulencia atenuada PE20191356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205439 2016-12-20
PCT/EP2017/083853 WO2018115140A2 (en) 2016-12-20 2017-12-20 Virulence attenuated bacteria based protein delivery

Publications (1)

Publication Number Publication Date
PE20191356A1 true PE20191356A1 (es) 2019-10-01

Family

ID=57629346

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001289A PE20191356A1 (es) 2016-12-20 2017-12-20 Suministro de proteinas basado en bacterias con virulencia atenuada

Country Status (29)

Country Link
US (2) US11518789B2 (es)
EP (2) EP3559022B1 (es)
JP (1) JP6976351B2 (es)
KR (1) KR102569949B1 (es)
CN (2) CN110325545B (es)
AU (1) AU2017384611B2 (es)
BR (1) BR112019012338A2 (es)
CA (1) CA3046852A1 (es)
CL (1) CL2019001698A1 (es)
CO (1) CO2019006675A2 (es)
CY (1) CY1124488T1 (es)
DK (1) DK3559022T3 (es)
EA (1) EA201991157A1 (es)
ES (1) ES2886672T3 (es)
HR (1) HRP20211516T1 (es)
HU (1) HUE055832T2 (es)
IL (1) IL267346A (es)
LT (1) LT3559022T (es)
MA (1) MA47119B1 (es)
MX (1) MX2019007264A (es)
MY (1) MY192537A (es)
NZ (1) NZ754510A (es)
PE (1) PE20191356A1 (es)
PH (1) PH12019550092A1 (es)
PL (1) PL3559022T3 (es)
PT (1) PT3559022T (es)
RS (1) RS62303B1 (es)
SI (1) SI3559022T1 (es)
WO (1) WO2018115140A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016027196B1 (pt) 2014-05-21 2023-05-02 Universität Basel Vetor e cepa bacteriana gram-negativa recombinante
CN108884466B (zh) 2015-11-19 2022-06-03 巴塞尔大学 基于细菌的蛋白递送
EP3377094B1 (en) 2015-11-19 2021-04-28 Universität Basel Virulence attenuated bacteria for treatment of malignant solid tumors
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
MY192537A (en) 2016-12-20 2022-08-26 Univ Basel Virulence attenuated bacteria based protein delivery
WO2020051197A1 (en) * 2018-09-06 2020-03-12 Dana-Farber Cancer Institute, Inc. Cgas/dncv-like nucleotidyltransferases and uses thereof
CN109825464B (zh) * 2019-01-17 2021-06-15 浙江海洋大学 敲除t6ss-1基因簇的杀香鱼假单胞菌鱼用减毒疫苗
US20220362361A1 (en) * 2019-10-18 2022-11-17 University Of Virginia Patent Foundation Compositions and methods for producing enhanced immune responses and rapid antibody production
WO2022067219A1 (en) * 2020-09-28 2022-03-31 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
CN116802196A (zh) * 2020-10-27 2023-09-22 T3制药股份公司 基于细菌的蛋白质递送
WO2022164937A1 (en) * 2021-01-26 2022-08-04 Christopher Bradley Treatment of cancer using mrna-mediated virus vaccination antigens delivered by attenuated bacteria
CN112852698B (zh) * 2021-01-30 2022-11-29 军事科学院军事医学研究院军事兽医研究所 牛种布鲁氏菌A19株asd基因缺失株的构建方法和应用
US20240165169A1 (en) * 2021-03-25 2024-05-23 T3 Pharmaceuticals Ag Pharmaceutical Combinations for Treating Cancer
CA3210774A1 (en) * 2021-03-25 2022-09-29 Simon ITTIG Pharmaceutical combinations for treating cancer
CN113480611B (zh) * 2021-06-28 2022-12-02 武汉大学 Rig-i的半胱天冬酶激活募集结构域抗病毒多肽、载体及其在制备抗病毒药物中的应用
CN113699088B (zh) * 2021-08-27 2023-09-15 集美大学 一株溶藻弧菌pstS基因稳定沉默菌株及其应用
CN114181881A (zh) * 2021-12-15 2022-03-15 浙江农林大学 基于氨基酸改造的新型减毒单增李斯特菌构建方法及应用
WO2023164454A2 (en) * 2022-02-22 2023-08-31 Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Compositions and methods for improved rhizobium-mediated plant transformation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU5209399A (en) 1998-07-10 2000-02-01 Cornell Research Foundation Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
US6291245B1 (en) * 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
AU2001294834A1 (en) 2000-09-26 2002-04-08 Beth Israel Deaconess Medical Center Recombinant bcg vaccines for the prevention and treatment of cancer
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
FR2862312B1 (fr) 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
WO2007044406A2 (en) * 2005-10-04 2007-04-19 Ludwig Institute For Cancer Research Methods for stimulating an immune response using bacterial antigen delivery system
WO2008019183A2 (en) 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EP2268313A2 (en) 2008-03-17 2011-01-05 Universitätsklinikum Münster Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
AU2015227479B2 (en) * 2008-11-21 2017-05-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
WO2014138324A1 (en) * 2013-03-07 2014-09-12 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
US10093708B2 (en) 2013-09-24 2018-10-09 Medicenna Therapeutics Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US10143743B2 (en) 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
BR112016027196B1 (pt) 2014-05-21 2023-05-02 Universität Basel Vetor e cepa bacteriana gram-negativa recombinante
CN108884466B (zh) 2015-11-19 2022-06-03 巴塞尔大学 基于细菌的蛋白递送
EP3377094B1 (en) 2015-11-19 2021-04-28 Universität Basel Virulence attenuated bacteria for treatment of malignant solid tumors
MY192537A (en) 2016-12-20 2022-08-26 Univ Basel Virulence attenuated bacteria based protein delivery

Also Published As

Publication number Publication date
US20200123207A1 (en) 2020-04-23
IL267346A (en) 2019-08-29
CA3046852A1 (en) 2018-06-28
CY1124488T1 (el) 2022-07-22
PH12019550092A1 (en) 2020-03-09
PT3559022T (pt) 2021-08-19
HRP20211516T1 (hr) 2021-12-24
ES2886672T3 (es) 2021-12-20
JP6976351B2 (ja) 2021-12-08
MA47119A (fr) 2019-10-30
EP3957645A1 (en) 2022-02-23
EA201991157A1 (ru) 2020-01-16
EP3559022B1 (en) 2021-06-30
WO2018115140A3 (en) 2018-08-09
PL3559022T3 (pl) 2021-12-20
LT3559022T (lt) 2021-08-25
CO2019006675A2 (es) 2019-09-18
HUE055832T2 (hu) 2021-12-28
MY192537A (en) 2022-08-26
NZ754510A (en) 2024-02-23
KR102569949B1 (ko) 2023-08-24
CL2019001698A1 (es) 2020-01-24
AU2017384611A1 (en) 2019-07-04
CN110325545A (zh) 2019-10-11
AU2017384611B2 (en) 2022-10-27
SI3559022T1 (sl) 2021-11-30
CN118006531A (zh) 2024-05-10
DK3559022T3 (da) 2021-09-27
EP3559022A2 (en) 2019-10-30
JP2020501609A (ja) 2020-01-23
MX2019007264A (es) 2019-11-18
BR112019012338A2 (pt) 2019-11-26
MA47119B1 (fr) 2021-09-30
US20230250138A1 (en) 2023-08-10
US11518789B2 (en) 2022-12-06
KR20190097154A (ko) 2019-08-20
CN110325545B (zh) 2024-02-09
RS62303B1 (sr) 2021-09-30
WO2018115140A2 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
PE20191356A1 (es) Suministro de proteinas basado en bacterias con virulencia atenuada
AU2017260389A1 (en) Chimeric neurotoxins
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
MX2018004475A (es) Agentes biologicos y su uso en plantas.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2016009898A (es) Tratamientos para acne resistente.
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
AR095232A1 (es) Métodos y composiciones para el control de malezas
BR112018009753A8 (pt) bactérias de virulência atenuada para o tratamento de tumores sólidos malignos
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
CL2019001002A1 (es) Métodos y composiciones para inmunoterapia por tusc2.
IN2014MU01100A (es)
EA202191631A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018074107A2 (pt) método para a redução da contaminação de ovos
CO2023006586A2 (es) Suministro de proteínas basado en bacterias
IL256162A (en) An amino thiol for use in the treatment of an infection caused by the bacterium mycobacterium spp.
BR112019003112A2 (pt) bactérias
JOP20200271A1 (ar) طرق لعلاج العدوى البكتيرية باستخدام المينوسيكلين
CY1124623T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CO2019006311A2 (es) N-acetilcisteína para su uso como agente antibacteriano
PE20180574A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina
AR104993A1 (es) Composiciones comprendiendo cepas bacterianas del género parabacteroides